SCHEMBL4808231

SCHEMBL4808231

Cc1c(Cl)cc(Cl)cc1C=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.57
TDP1 Q9NUW8 1/20 0.50
PTPN1 P18031 2/20 0.41
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 8/20 0.36
ORAI1 Q96D31 1/20 0.35
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MPI P34949 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 3/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27290171 0.82 ERN1 (0.52) ERN1TDP1PTPN1CYP3A4CYP1A2
SCHEMBL27503497 0.78 ALDH1A1 (0.41) ERN1TDP1PTPN1CYP3A4CYP1A2
SCHEMBL11176138 0.78 ERN1 (0.44) ERN1TDP1PTPN1CYP3A4CYP1A2
SCHEMBL14877158 0.78 ERN1 (0.64) ERN1TDP1PTPN1CYP3A4ALDH1A1
SCHEMBL189844 0.76 ERN1 (0.61) ERN1TDP1PTPN1CYP3A4ALDH1A1
SCHEMBL14876731 0.74 ERN1 (0.54) ERN1TDP1PTPN1CYP3A4CYP1A2
SCHEMBL98117 0.74 ALDH1A1 (0.53) CYP3A4ALDH1A1MEN1MAPTKMT2A
SCHEMBL17512175 0.73 ERN1 (0.57) ERN1TDP1PTPN1CYP3A4ALDH1A1
SCHEMBL10490659 0.73 TDP1 (0.40) ERN1TDP1PTPN1CYP3A4CYP1A2
SCHEMBL29382880 0.73 ERN1 (1.00) ERN1TDP1CYP3A4ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8323621-B2 site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle VANDERBILT UNIVERSITY (US) 2012-12-04 US disclosed
US-20080241873-A1 MULTI-USE MULTIMODAL IMAGING CHELATES BORNHOP DARRYL J 2008-10-02 US disclosed
US-20080241074-A1 MULTI-USE MULTIMODAL IMAGING CHELATES VANDERBILT UNIVERSITY 2008-10-02 US disclosed
US-7338651-B2 Multi-use multimodal imaging chelates TEXAS TECH UNIVERSITY SYSTEM (US) 2008-03-04 US disclosed
EP-1429783-A4 MULTI-USE MULTIMODAL IMAGING CHELATES UNIV TEXAS TECH (US) 2006-08-09 EP disclosed
EP-1429783-A2 MULTI-USE MULTIMODAL IMAGING CHELATES TEXAS TECH UNIVERSITY (US) 2004-06-23 EP disclosed
WO-2003020701-A9 MULTI-USE MULTIMODAL IMAGING CHELATES UNIV TEXAS TECH (US) 2003-09-12 WO disclosed
US-20030129579-A1 Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. VANDERBILT UNIVERSITY 2003-07-10 US disclosed
WO-2003020701-A2 MULTI-USE MULTIMODAL IMAGING CHELATES TEXAS TECH UNIVERSITY (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241074-A1 MULTI-USE MULTIMODAL IMAGING CHELATES PCNA, CLTC, CLTB ERN1 4807/4885TDP1 2660/4885PTPN1 4715/4885
US-20030129579-A1 Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. PCNA, CLTC, PHOSPHO1 ERN1 4611/4885TDP1 1879/4885PTPN1 4657/4885
US-20080241873-A1 MULTI-USE MULTIMODAL IMAGING CHELATES PCNA, CLTC, CLTB ERN1 4807/4885TDP1 2660/4885PTPN1 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.